Could a clotting protein be the first treatment for bleeding stroke?
Disease control
Recruiting now
This Phase 3 trial tests whether a clotting drug called recombinant factor VIIa can improve outcomes for people having a hemorrhagic stroke (bleeding in the brain). The drug is given within 2 hours of stroke onset. The study will enroll 350 adults aged 18-80. Half get the drug, h…
Phase 3 • Sponsor: Joseph Broderick, MD • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC